{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T16:44:28Z","timestamp":1785775468992,"version":"3.56.0"},"reference-count":72,"publisher":"The Endocrine Society","license":[{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"National Health and Medical Research Council Centre for Research Excellence","award":["APP2024615"],"award-info":[{"award-number":["APP2024615"]}]},{"name":"Primary Aldosteronism Centre of Excellence Career Establishment Program Grant"},{"DOI":"10.13039\/501100014643","name":"Baker Heart and Diabetes Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014643","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000923","name":"Australian Research Council","doi-asserted-by":"publisher","award":["DP230103229"],"award-info":[{"award-number":["DP230103229"]}],"id":[{"id":"10.13039\/501100000923","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001030","name":"National Heart Foundation of Australia","doi-asserted-by":"publisher","award":["106729"],"award-info":[{"award-number":["106729"]}],"id":[{"id":"10.13039\/501100001030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP2041474"],"award-info":[{"award-number":["APP2041474"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Victorian Government\u2019s Operational Infrastructure Scheme"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Low-renin hypertension is increasingly recognized as a common and clinically important form of hypertension. Expanded screening for primary aldosteronism has revealed many individuals with suppressed renin who do not meet the diagnostic criteria for aldosterone excess, yet exhibit features consistent with sodium retention or increased mineralocorticoid receptor activity.<\/jats:p>\n                  <jats:p>This review synthesizes evidence from targeted literature searches on the epidemiology, mechanisms, diagnostic challenges, and treatment of low-renin hypertension. Early studies proposed renin, in the presence of hypertension, as a marker of excess sodium retention and volume expansion, suggesting that renin could guide individualized therapy. Adoption of a renin-guided treatment approach was historically limited by assay variability and concerns regarding adverse effects from high-dose mineralocorticoid receptor antagonists. However, improvements in renin assay performance, increased accessibility and use of renin testing, and the availability of lower-dose and better-tolerated mineralocorticoid receptor antagonists have renewed interest in this strategy.<\/jats:p>\n                  <jats:p>Low-renin hypertension encompasses primary aldosteronism, conditions that mimic mineralocorticoid excess, and disorders of renal tubular sodium transport. Across this spectrum, patients respond more favorably to therapies targeting sodium retention: mineralocorticoid receptor antagonists, epithelial sodium channel inhibitors, or thiazide diuretics, than to agents directed primarily at vasoconstriction.<\/jats:p>\n                  <jats:p>Recognition of low-renin hypertension as a distinct phenotype enables mechanism-based therapy and may improve blood pressure control, reduce medication burden, and mitigate long-term cardiovascular risk.<\/jats:p>","DOI":"10.1210\/clinem\/dgag292","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T11:38:55Z","timestamp":1784893135000},"source":"Crossref","is-referenced-by-count":0,"title":["Low-renin hypertension: a distinct phenotype enabling mechanism-based treatment"],"prefix":"10.1210","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5789-383X","authenticated-orcid":false,"given":"Sonali S","family":"Shah","sequence":"first","affiliation":[{"name":"Center for Endocrinology and Reproductive Health, Hudson Institute of Medical Research , Clayton, Vic 3168 ,","place":["Australia"]},{"name":"Department of Endocrinology, Monash Health , Clayton, Vic 3168 ,","place":["Australia"]},{"name":"Department of Molecular and Translational Science, Monash University , Clayton, Vic 3168 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0948-2072","authenticated-orcid":false,"given":"Peter J","family":"Fuller","sequence":"additional","affiliation":[{"name":"Center for Endocrinology and Reproductive Health, Hudson Institute of Medical Research , Clayton, Vic 3168 ,","place":["Australia"]},{"name":"Department of Endocrinology, Monash Health , Clayton, Vic 3168 ,","place":["Australia"]},{"name":"Department of Molecular and Translational Science, Monash University , Clayton, Vic 3168 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0450-5375","authenticated-orcid":false,"given":"Morag J","family":"Young","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Endocrinology, Baker Heart and Diabetes Institute , Melbourne, Vic 3004 ,","place":["Australia"]},{"name":"School of Translational Science, Monash University , Melbourne, Vic 3004 ,","place":["Australia"]},{"name":"The Baker and University of Melbourne Department of Cardiometabolic Health and Disease, University of Melbourne , Parkville, Vic 3010 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4620-4976","authenticated-orcid":false,"given":"Jun","family":"Yang","sequence":"additional","affiliation":[{"name":"Center for Endocrinology and Reproductive Health, Hudson Institute of Medical Research , Clayton, Vic 3168 ,","place":["Australia"]},{"name":"Department of Endocrinology, Monash Health , Clayton, Vic 3168 ,","place":["Australia"]},{"name":"Department of Molecular and Translational Science, Monash University , Clayton, Vic 3168 ,","place":["Australia"]},{"name":"Department of Medicine, Monash University , Clayton, Vic 3168 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"issue":"14","key":"2026080311463113000_dgag292-B1","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1001\/jama.2023.3322","article-title":"Heterogeneity in blood pressure response to 4 antihypertensive drugs: a randomized clinical trial","volume":"329","author":"Sundstrom","year":"2023","journal-title":"JAMA"},{"issue":"12","key":"2026080311463113000_dgag292-B2","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1001\/jama.2020.14545","article-title":"Trends in blood pressure control among US adults with hypertension, 1999-2000 to 2017-2018","volume":"324","author":"Muntner","year":"2020","journal-title":"JAMA"},{"issue":"9","key":"2026080311463113000_dgag292-B3","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1210\/clinem\/dgaf284","article-title":"Primary aldosteronism: an endocrine society clinical practice guideline","volume":"110","author":"Adler","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"14","key":"2026080311463113000_dgag292-B4","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/j.jacc.2017.01.052","article-title":"Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice","volume":"69","author":"Monticone","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"2026080311463113000_dgag292-B5","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvae113","article-title":"Prevalence and characteristics of low-renin hypertension in a primary care population","volume":"8","author":"Shah","year":"2024","journal-title":"J Endocr Soc"},{"key":"2026080311463113000_dgag292-B6","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41371-026-01148-3","article-title":"Prevalence, clinical characteristics and management of low-renin hypertension: a real-world cohort study","volume":"40","author":"Shah","year":"2026","journal-title":"J Hum Hypertens"},{"issue":"2","key":"2026080311463113000_dgag292-B7","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1001\/jama.1979.03290280031022","article-title":"Renin profiling for diagnosis and treatment of hypertension","volume":"241","author":"Laragh","year":"1979","journal-title":"JAMA"},{"issue":"5","key":"2026080311463113000_dgag292-B8","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/s41371-023-00891-1","article-title":"Efficacy and safety of mineralocorticoid receptor antagonists for the treatment of low-renin hypertension: a systematic review and meta-analysis","volume":"38","author":"Shah","year":"2024","journal-title":"J Hum Hypertens"},{"issue":"38","key":"2026080311463113000_dgag292-B9","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","article-title":"2024 ESC guidelines for the management of elevated blood pressure and hypertension","volume":"45","author":"McEvoy","year":"2024","journal-title":"Eur Heart J"},{"issue":"2","key":"2026080311463113000_dgag292-B10","doi-asserted-by":"crossref","first-page":"85","DOI":"10.5694\/mja16.00526","article-title":"Guideline for the diagnosis and management of hypertension in adults\u20142016","volume":"205","author":"Gabb","year":"2016","journal-title":"Med J Aust"},{"issue":"9","key":"2026080311463113000_dgag292-B11","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1056\/NEJM197203022860901","article-title":"Essential hypertension: renin and aldosterone, heart attack and stroke","volume":"286","author":"Brunner","year":"1972","journal-title":"N Engl J Med"},{"issue":"12","key":"2026080311463113000_dgag292-B12","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-003733","article-title":"Global, regional and national sodium intakes in 1990 and 2010: a systematic analysis of 24h urinary sodium excretion and dietary surveys worldwide","volume":"3","author":"Powles","year":"2013","journal-title":"BMJ open"},{"issue":"3","key":"2026080311463113000_dgag292-B13","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1001\/archinte.1967.00290210064002","article-title":"Plasma renin activity in healthy subjects and patients with hypertension. Preliminary experience with a rapid and quantitative bio-assay","volume":"119","author":"Gunnells","year":"1967","journal-title":"Arch Intern Med"},{"issue":"10","key":"2026080311463113000_dgag292-B14","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1210\/jcem-29-10-1349","article-title":"Application of a radioimmunoassay for angiotensin I to the physiologic measurements of plasma renin activity in normal human subjects","volume":"29","author":"Haber","year":"1969","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2026080311463113000_dgag292-B15","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1210\/jcem-48-6-1041","article-title":"Direct radioimmunoassay of human renin","volume":"48","author":"Galen","year":"1979","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl 1","key":"2026080311463113000_dgag292-B16","article-title":"Raas triple a-testing","volume":"36","author":"Poglitsch","year":"2018","journal-title":"J Hypertens"},{"issue":"3","key":"2026080311463113000_dgag292-B17","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1093\/clinchem\/hvaa001","article-title":"Measurement of equilibrium angiotensin II in the diagnosis of primary aldosteronism","volume":"66","author":"Guo","year":"2020","journal-title":"Clin Chem"},{"issue":"1","key":"2026080311463113000_dgag292-B18","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1161\/HYPERTENSIONAHA.119.13772","article-title":"Renin-angiotensin-aldosterone system triple-A analysis for the screening of primary aldosteronism","volume":"75","author":"Burrello","year":"2020","journal-title":"Hypertension"},{"issue":"9","key":"2026080311463113000_dgag292-B19","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/s41371-019-0291-y","article-title":"Mild primary aldosteronism (PA) followed by overt PA are possibly the most common forms of low renin hypertension: a single-center retrospective study","volume":"34","author":"Luo","year":"2020","journal-title":"J Hum Hypertens"},{"issue":"1","key":"2026080311463113000_dgag292-B20","doi-asserted-by":"crossref","first-page":"18091","DOI":"10.1038\/s41598-024-67261-w","article-title":"Evaluation of aldosterone to direct renin ratio, low renin and related Phenotypes in Afro-Colombian patients with apparent treatment resistant hypertension","volume":"14","author":"Duran","year":"2024","journal-title":"Sci Rep"},{"issue":"11","key":"2026080311463113000_dgag292-B21","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1097\/00004872-200411000-00026","article-title":"Low-renin status in therapy-resistant hypertension: a clue to efficient treatment","volume":"22","author":"Eide","year":"2004","journal-title":"J Hypertens"},{"issue":"3-4","key":"2026080311463113000_dgag292-B22","first-page":"139","article-title":"Plasma renin activity and plasma aldosterone concentrations in untreated Nigerians with essential hypertension","volume":"13","author":"Osotimehin","year":"1984","journal-title":"Afr J Med Med Sci"},{"issue":"4","key":"2026080311463113000_dgag292-B23","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1161\/01.HYP.0000013784.18175.51","article-title":"Familial aggregation of low-renin hypertension","volume":"39","author":"Fisher","year":"2002","journal-title":"Hypertension"},{"issue":"6","key":"2026080311463113000_dgag292-B24","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1093\/ajh\/hpt276","article-title":"Association of renin and aldosterone with ethnicity and blood pressure: the multi-ethnic study of atherosclerosis","volume":"27","author":"Rifkin","year":"2014","journal-title":"Am J Hypertens"},{"issue":"4","key":"2026080311463113000_dgag292-B25","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1097\/HJH.0000000000003377","article-title":"The effect of age, sex and BMI on the aldosterone-to-renin ratio in essential hypertensive individuals","volume":"41","author":"Alnazer","year":"2023","journal-title":"J Hypertens"},{"issue":"9","key":"2026080311463113000_dgag292-B26","doi-asserted-by":"crossref","first-page":"630","DOI":"10.7326\/M17-0882","article-title":"The spectrum of subclinical primary aldosteronism and incident hypertension: a cohort study","volume":"167","author":"Brown","year":"2017","journal-title":"Ann Intern Med"},{"issue":"13","key":"2026080311463113000_dgag292-B27","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1161\/CIRCULATIONAHA.124.073507","article-title":"Subclinical primary aldosteronism and Major adverse cardiovascular events: a longitudinal population-based cohort study","volume":"152","author":"Goupil","year":"2025","journal-title":"Circulation"},{"issue":"4","key":"2026080311463113000_dgag292-B28","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1161\/01.HYP.0000258554.87444.91","article-title":"Clinical and genetic correlates of aldosterone-to-renin ratio and relations to blood pressure in a community sample","volume":"49","author":"Newton-Cheh","year":"2007","journal-title":"Hypertension"},{"issue":"24","key":"2026080311463113000_dgag292-B29","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.023082","article-title":"Heightened cardiovascular risk in hypertension associated with renin-independent aldosteronism versus renin-dependent aldosteronism: a collaborative study","volume":"10","author":"Hu","year":"2021","journal-title":"J Am Heart Assoc"},{"issue":"8","key":"2026080311463113000_dgag292-B30","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1097\/00004872-200208000-00002","article-title":"Mineralocorticoid receptors and pathophysiological roles for aldosterone in the cardiovascular system","volume":"20","author":"Young","year":"2002","journal-title":"J Hypertens"},{"issue":"6","key":"2026080311463113000_dgag292-B31","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1042\/EBC20210006","article-title":"Mineralocorticoid receptor actions in cardiovascular development and disease","volume":"65","author":"Young","year":"2021","journal-title":"Essays Biochem"},{"issue":"2","key":"2026080311463113000_dgag292-B32","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.mce.2011.06.014","article-title":"Mineralocorticoid receptors in vascular function and disease","volume":"350","author":"McCurley","year":"2012","journal-title":"Mol Cell Endocrinol"},{"issue":"9","key":"2026080311463113000_dgag292-B33","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1038\/nm.2891","article-title":"Direct regulation of blood pressure by smooth muscle cell mineralocorticoid receptors","volume":"18","author":"McCurley","year":"2012","journal-title":"Nat Med"},{"issue":"3","key":"2026080311463113000_dgag292-B34","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1161\/HYPERTENSIONAHA.109.131110","article-title":"Deletion of mineralocorticoid receptors from macrophages protects against deoxycorticosterone\/salt-induced cardiac fibrosis and increased blood pressure","volume":"54","author":"Rickard","year":"2009","journal-title":"Hypertension"},{"issue":"4","key":"2026080311463113000_dgag292-B35","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1161\/01.HYP.0000184231.84465.62","article-title":"Low-renin hypertension with relative aldosterone excess is associated with impaired NO-mediated vasodilation","volume":"46","author":"Duffy","year":"2005","journal-title":"Hypertension"},{"issue":"2","key":"2026080311463113000_dgag292-B36","doi-asserted-by":"crossref","first-page":"H575","DOI":"10.1152\/ajpheart.00331.2003","article-title":"Effect of high-salt diet on NO release and superoxide production in rat aorta","volume":"286","author":"Zhu","year":"2004","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2026080311463113000_dgag292-B37","article-title":"The multifaceted impact of a high-salt environment on the immune system and its contribution to salt-sensitive hypertension","volume":"44","author":"Wang","year":"2025","journal-title":"Biochem Biophys Rep"},{"issue":"10008","key":"2026080311463113000_dgag292-B38","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"issue":"6","key":"2026080311463113000_dgag292-B39","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S2213-8587(18)30071-8","article-title":"Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies","volume":"6","author":"Williams","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"2026080311463113000_dgag292-B40","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/ehjcvp\/pvab031","article-title":"Spironolactone effect on the blood pressure of patients at risk of developing heart failure: an analysis from the HOMAGE trial","volume":"8","author":"Ferreira","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"6","key":"2026080311463113000_dgag292-B41","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1210\/endo.132.6.8504732","article-title":"Licorice inhibits 11 beta-hydroxysteroid dehydrogenase messenger ribonucleic acid levels and potentiates glucocorticoid hormone action","volume":"132","author":"Whorwood","year":"1993","journal-title":"Endocrinology"},{"key":"2026080311463113000_dgag292-B42","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2021.111168","article-title":"Antifungal therapy with azoles and the syndrome of acquired mineralocorticoid excess","volume":"524","author":"Beck","year":"2021","journal-title":"Mol Cell Endocrinol"},{"issue":"52","key":"2026080311463113000_dgag292-B43","doi-asserted-by":"crossref","first-page":"E11248","DOI":"10.1073\/pnas.1716621115","article-title":"Clinical, genetic, and structural basis of apparent mineralocorticoid excess due to 11beta-hydroxysteroid dehydrogenase type 2 deficiency","volume":"114","author":"Yau","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"2026080311463113000_dgag292-B44","first-page":"3617","article-title":"11 beta-hydroxysteroid dehydrogenase activity in Cushing's syndrome: explaining the mineralocorticoid excess state of the ectopic adrenocorticotropin syndrome","volume":"80","author":"Stewart","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2026080311463113000_dgag292-B45","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/S2213-8587(21)00235-7","article-title":"Consensus on diagnosis and management of Cushing's disease: a guideline update","volume":"9","author":"Fleseriu","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026080311463113000_dgag292-B46","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.846865","article-title":"11-Deoxycorticosterone producing adrenal hyperplasia as a very unusual cause of endocrine hypertension: case report and systematic review of the literature","volume":"13","author":"Asla","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5476","key":"2026080311463113000_dgag292-B47","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1126\/science.289.5476.119","article-title":"Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy","volume":"289","author":"Geller","year":"2000","journal-title":"Science"},{"issue":"19","key":"2026080311463113000_dgag292-B48","doi-asserted-by":"crossref","DOI":"10.3390\/ijms221910839","article-title":"Primary generalized glucocorticoid resistance and hypersensitivity syndromes: a 2021 update","volume":"22","author":"Nicolaides","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"3","key":"2026080311463113000_dgag292-B49","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/0092-8674(94)90250-X","article-title":"Liddle's syndrome: heritable human hypertension caused by mutations in the beta subunit of the epithelial sodium channel","volume":"79","author":"Shimkets","year":"1994","journal-title":"Cell"},{"issue":"11","key":"2026080311463113000_dgag292-B50","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1681\/ASN.2016111163","article-title":"A missense mutation in the extracellular domain of alphaENaC causes Liddle syndrome","volume":"28","author":"Salih","year":"2017","journal-title":"J Am Soc Nephrol"},{"issue":"5532","key":"2026080311463113000_dgag292-B51","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1126\/science.1062844","article-title":"Human hypertension caused by mutations in WNK kinases","volume":"293","author":"Wilson","year":"2001","journal-title":"Science"},{"issue":"7","key":"2026080311463113000_dgag292-B52","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1210\/jc.2016-1472","article-title":"Study heterogeneity and estimation of prevalence of primary aldosteronism: a systematic review and meta-regression analysis","volume":"101","author":"Kayser","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2026080311463113000_dgag292-B53","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1056\/NEJMc2508629","article-title":"Phase 2a study of baxdrostat in primary aldosteronism","volume":"393","author":"Turcu","year":"2025","journal-title":"N Engl J Med"},{"issue":"9","key":"2026080311463113000_dgag292-B54","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1210\/clinem\/dgae145","article-title":"The spectrum of dysregulated aldosterone production: an international human physiology study","volume":"109","author":"Parksook","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026080311463113000_dgag292-B55","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1161\/HYPERTENSIONAHA.123.21983","article-title":"Long-term follow-up of patients with elevated aldosterone-to-renin ratio but negative confirmatory test: the progression of primary aldosteronism phenotypes","volume":"81","author":"Buffolo","year":"2024","journal-title":"Hypertension"},{"issue":"4","key":"2026080311463113000_dgag292-B56","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1161\/CIRCULATIONAHA.117.028201","article-title":"Age-related autonomous aldosteronism","volume":"136","author":"Nanba","year":"2017","journal-title":"Circulation"},{"issue":"6","key":"2026080311463113000_dgag292-B57","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1055\/a-1128-0421","article-title":"The potential role of aldosterone-producing cell clusters in adrenal disease","volume":"52","author":"Lim","year":"2020","journal-title":"Horm Metab Res"},{"issue":"33","key":"2026080311463113000_dgag292-B58","doi-asserted-by":"crossref","first-page":"E4591","DOI":"10.1073\/pnas.1505529112","article-title":"Aldosterone-stimulating somatic gene mutations are common in normal adrenal glands","volume":"112","author":"Nishimoto","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2026080311463113000_dgag292-B59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13023-025-04160-x","article-title":"Population-based estimates of the global prevalence and carrier frequency of apparent mineralocorticoid excess caused by 11beta-hydroxysteroid dehydrogenase type 2 deficiency","volume":"21","author":"Charoenngam","year":"2025","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"2026080311463113000_dgag292-B60","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s12020-021-02783-1","article-title":"Extending the endocrine hypertension spectrum: novel nonclassic apparent mineralocorticoid excess","volume":"74","author":"Carvajal","year":"2021","journal-title":"Endocrine"},{"issue":"2","key":"2026080311463113000_dgag292-B61","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1210\/jc.2018-01197","article-title":"Clinical, biochemical, and genetic characteristics of \u201cnonclassic\u201d apparent mineralocorticoid excess syndrome","volume":"104","author":"Tapia-Castillo","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"4-6","key":"2026080311463113000_dgag292-B62","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/0960-0760(91)90268-A","article-title":"Mineralocorticoids in congenital adrenal hyperplasia","volume":"40","author":"Biglieri","year":"1991","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"9","key":"2026080311463113000_dgag292-B63","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/ajh\/hpx066","article-title":"Physiological phenotyping for personalized therapy of uncontrolled hypertension in Africa","volume":"30","author":"Akintunde","year":"2017","journal-title":"Am J Hypertens"},{"issue":"5","key":"2026080311463113000_dgag292-B64","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1093\/ajh\/hpw167","article-title":"High frequency of variants of candidate genes in black Africans with low renin-resistant hypertension","volume":"30","author":"Jones","year":"2017","journal-title":"Am J Hypertens"},{"issue":"24","key":"2026080311463113000_dgag292-B65","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1161\/CIRCULATIONAHA.120.050896","article-title":"Association of serum aldosterone and plasma renin activity with ambulatory blood pressure in African Americans: the Jackson heart study","volume":"143","author":"Joseph","year":"2021","journal-title":"Circulation"},{"issue":"6","key":"2026080311463113000_dgag292-B66","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/sj.jhh.1001182","article-title":"T594m and G442V polymorphisms of the sodium channel beta subunit and hypertension in a black population","volume":"15","author":"Dong","year":"2001","journal-title":"J Hum Hypertens"},{"issue":"1","key":"2026080311463113000_dgag292-B67","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1161\/01.HYP.0000022570.02119.75","article-title":"Amiloride, a specific drug for hypertension in black people with T594M variant?","volume":"40","author":"Baker","year":"2002","journal-title":"Hypertension"},{"issue":"9113","key":"2026080311463113000_dgag292-B68","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/S0140-6736(97)07306-6","article-title":"Association of hypertension with T594M mutation in beta subunit of epithelial sodium channels in black people resident in London","volume":"351","author":"Baker","year":"1998","journal-title":"Lancet"},{"issue":"3","key":"2026080311463113000_dgag292-B69","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1161\/01.HYP.0000200704.45994.ff","article-title":"Epithelial sodium channel allele T594M is not associated with blood pressure or blood pressure response to amiloride","volume":"47","author":"Hollier","year":"2006","journal-title":"Hypertension"},{"issue":"Suppl 1","key":"2026080311463113000_dgag292-B70","first-page":"i65","article-title":"Effects of finerenone on cardiorenal outcomes in blood pressure subgroups in patients with CKD and T2D. Conference Abstract","volume":"36","author":"Ruilope","year":"2021","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"2026080311463113000_dgag292-B71","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s40119-021-00233-7","article-title":"Aprocitentan, A dual endothelin receptor antagonist under development for the treatment of resistant hypertension. Review","volume":"10","author":"Angeli","year":"2021","journal-title":"Cardiol Ther"},{"issue":"9","key":"2026080311463113000_dgag292-B72","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/s41371-024-00931-4","article-title":"A randomized trial assessing efficacy and safety of mineralocorticoid receptor antagonist therapy compared to standard antihypertensive therapy in hypErtension with low renin (REMASTER): rationale and study design","volume":"38","author":"Shah","year":"2024","journal-title":"J Hum Hypertens"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgag292\/70149020\/dgag292.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgag292\/70149020\/dgag292.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T15:46:46Z","timestamp":1785772006000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article\/doi\/10.1210\/clinem\/dgag292\/8742191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":72,"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgag292","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,27]]},"article-number":"dgag292"}}